|
SUMO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.23669987981157E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.74129999811024E-08 |
| Normal-vs-Stage2 |
5.93349999999937E-05 |
| Normal-vs-Stage3 |
3.82370000107102E-08 |
| Normal-vs-Stage4 |
2.78630007954916E-10 |
| Stage1-vs-Stage2 |
6.912200E-01 |
| Stage1-vs-Stage3 |
3.350000E-01 |
| Stage1-vs-Stage4 |
5.630000E-02 |
| Stage2-vs-Stage3 |
8.408000E-01 |
| Stage2-vs-Stage4 |
4.438800E-01 |
| Stage3-vs-Stage4 |
4.165400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.808699939294E-10 |
| Normal-vs-AfricanAmerican |
2.704400E-02 |
| Normal-vs-Asian |
9.67000000073881E-08 |
| Caucasian-vs-AfricanAmerican |
1.435350E-01 |
| Caucasian-vs-Asian |
7.766600E-01 |
| AfricanAmerican-vs-Asian |
3.040800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.24069998508736E-09 |
| Normal-vs-Female |
1.0239999959083E-09 |
| Male-vs-Female |
6.457200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.5622999994267E-08 |
| Normal-vs-Age(41-60Yrs) |
4.10580003329386E-09 |
| Normal-vs-Age(61-80Yrs) |
2.14440000201321E-08 |
| Normal-vs-Age(81-100Yrs) |
1.975540E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.474800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.374600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.609000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.429400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.392400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.141200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.442000E-01 |
| Classical-VS-Follicular |
8.811200E-01 |
| Classical-VS-Other |
7.461000E-01 |
| Classical-VS-Normal |
2.72680000801273E-09 |
| Tall-VS-Follicular |
6.157400E-01 |
| Tall-VS-Other |
9.937600E-01 |
| Tall-VS-Normal |
1.8656999999922E-05 |
| Follicular-VS-Other |
7.848200E-01 |
| Follicular-VS-Normal |
2.05549999999777E-05 |
| Other-VS-Normal |
8.056200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.6892999483461E-09 |
| Normal-vs-N1 |
9.04154529024481E-12 |
| N0-vs-N1 |
2.038000E-02 |
|
|
